ABIOMED (ABMD) Given New $265.00 Price Target at Leerink Swann

ABIOMED (NASDAQ:ABMD) had its price target boosted by equities researchers at Leerink Swann from $200.00 to $265.00 in a research note issued on Friday, Marketbeat.com reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Leerink Swann’s price objective suggests a potential upside of 16.08% from the company’s previous close.

A number of other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of ABIOMED from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. BTIG Research lowered shares of ABIOMED from a “buy” rating to a “neutral” rating in a research report on Monday, October 16th. Piper Jaffray Companies boosted their price objective on shares of ABIOMED to $200.00 and gave the company an “overweight” rating in a research report on Thursday, October 26th. Jefferies Group boosted their price objective on shares of ABIOMED from $208.00 to $220.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. Finally, BidaskClub lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. ABIOMED currently has an average rating of “Buy” and a consensus target price of $210.50.

ABIOMED (NASDAQ ABMD) traded up $2.40 during trading hours on Friday, hitting $228.29. 179,201 shares of the stock were exchanged, compared to its average volume of 265,059. The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $10,200.00, a price-to-earnings ratio of 112.46, a PEG ratio of 2.98 and a beta of 0.15. ABIOMED has a twelve month low of $103.53 and a twelve month high of $229.05.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.16. The business had revenue of $132.80 million during the quarter, compared to analyst estimates of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The company’s revenue was up 28.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.20 earnings per share. equities analysts expect that ABIOMED will post 2.41 earnings per share for the current year.

In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the completion of the sale, the vice president now directly owns 56,757 shares in the company, valued at $10,139,070.48. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Dorothy E. Puhy sold 6,364 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the sale, the director now owns 39,532 shares of the company’s stock, valued at $7,079,390.56. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABMD. Schwab Charles Investment Management Inc. grew its stake in ABIOMED by 6.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 120,219 shares of the medical equipment provider’s stock worth $17,228,000 after buying an additional 6,935 shares during the period. JPMorgan Chase & Co. grew its stake in ABIOMED by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 14,094 shares of the medical equipment provider’s stock worth $2,019,000 after buying an additional 680 shares during the period. Schroder Investment Management Group purchased a new stake in ABIOMED during the second quarter worth approximately $716,000. Wells Fargo & Company MN grew its stake in ABIOMED by 9.0% during the second quarter. Wells Fargo & Company MN now owns 15,712 shares of the medical equipment provider’s stock worth $2,252,000 after buying an additional 1,297 shares during the period. Finally, Riverhead Capital Management LLC grew its stake in ABIOMED by 73.3% during the second quarter. Riverhead Capital Management LLC now owns 3,120 shares of the medical equipment provider’s stock worth $447,000 after buying an additional 1,320 shares during the period. Institutional investors own 90.75% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/20/abiomed-abmd-given-new-265-00-price-target-at-leerink-swann.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Leave a Reply